Hot Life Science Investor Mandate 3: Global PE Company Looking for Early Stage Therapeutics

12 Jun

A global PE company with dedicated Life Science investment funds is looking to provide seed, venture and growth capital to companies in the life science space.  The firm’s investment size is highly variable depending on the stage and financial needs of each company and the firm has no target number of investments it plans to make over the next 6-9 months. The firm is willing to consider investment located globally.

The firm is focuses on a new investment approach to developing pharmaceutical assets in a capital efficient fashion, to a human proof-of-concept in single asset companies  that are anywhere from 12-18 months to IND to proof of concept (Phase IIa). The fund is currently most interested in small molecule therapeutics or IND-ready biologics for indications of metabolic disease, diseases of the blood, inflammation, and oncology. The firm is also willing to invest in highly differentiated biological compounds if compelling opportunities arise.  The firm is also less inclined to invest into orphan indication.

The firm’s requirements for management teams vary on a case by case basis and the firm is open to discussion in this area.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: